Widschwendter M et al. |
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. |
2015 |
EBioMedicine |
pmid:26629528
|
Rachner TD and Rauner M |
RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers. |
2015 |
EBioMedicine |
pmid:26629502
|
Gennaro G et al. |
Green Tea Modulates Cytokine Expression in the Periodontium and Attenuates Alveolar Bone Resorption in Type 1 Diabetic Rats. |
2015 |
PLoS ONE |
pmid:26270535
|
Kastritis E et al. |
Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. |
2015 |
Blood Cancer J |
pmid:26047389
|
Janda K et al. |
Cardiovascular risk in chronic kidney disease patients: intima-media thickness predicts the incidence and severity of histologically assessed medial calcification in radial arteries. |
2015 |
BMC Nephrol |
pmid:26037625
|
Davenport C et al. |
The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. |
2015 |
Eur. J. Endocrinol. |
pmid:26036811
|
Zhao L et al. |
Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. |
2015 |
J. Nutr. Biochem. |
pmid:26239832
|
de Molon RS et al. |
OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. |
2015 |
J. Bone Miner. Res. |
pmid:25727550
|
Nagy V and Penninger JM |
The RANKL-RANK Story. |
2015 |
Gerontology |
pmid:25720990
|
Maser RE et al. |
Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes. |
2015 |
Endocr Pract |
pmid:25100392
|